Anthropic buys biotech AI startup Coefficient Bio for $400 million

Anthropic has acquired stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to reports from The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch that it closed, though they declined to comment on the purchase amount.

The acquisition comes as Anthropic expands its presence in healthcare and life sciences. The company announced Claude for Life Sciences in October, a tool designed to help scientific researchers make discoveries.

What's the news?

Anthropic purchased Coefficient Bio, a young biotech AI startup that was operating in stealth mode. The deal is worth $400 million in stock, though Anthropic hasn't officially confirmed the financial details.

Key details about the acquisition:

• Coefficient Bio was founded just eight months ago
• The startup had around 10 employees
• The team is expected to join Anthropic's health and life science division
• Both companies focus on using AI to improve biological research

Why does it matter?

This acquisition signals Anthropic's serious commitment to the healthcare and life sciences market. The company isn't just building general AI tools - it's investing heavily in specialized applications for scientific research.

For the broader AI industry, the deal shows how major AI companies are moving beyond chatbots and general-purpose tools. They're targeting specific industries where AI can solve complex, high-value problems.

The $400 million price tag for such a young company also highlights how much value investors and acquirers see in AI-powered drug discovery and biological research tools.

The context

Coefficient Bio's founders, Samuel Stanton and Nathan C. Frey, both worked in computational drug discovery at Genentech's Prescient Design before starting their company. This background gave them direct experience in how pharmaceutical companies approach AI-powered research.

The startup was using AI to make drug discovery and other forms of biological research more efficient. Drug discovery typically takes years and costs billions of dollars, so any technology that can speed up the process has huge potential value.

Anthropic launched Claude for Life Sciences in October, positioning itself as a serious player in scientific research. The Coefficient Bio acquisition gives Anthropic a dedicated team with deep expertise in computational biology and drug discovery, rather than trying to build this knowledge from scratch.